190 related articles for article (PubMed ID: 31954536)
21. Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma.
Sia TY; Huang Y; Gockley A; Melamed A; Khoury-Collado F; St Clair C; Hou JY; Tergas AI; Hershman DL; Wright JD
Gynecol Oncol; 2021 Jun; 161(3):734-740. PubMed ID: 33810881
[TBL] [Abstract][Full Text] [Related]
22. Proposing the 3-tier staging system for improving prognostication in Stage I uterine leiomyosarcoma.
Matsuo K; Matsuzaki S; Nusbaum DJ; Nagase Y; Hur EY; Klar M; Roman LD
J Surg Oncol; 2021 Mar; 123(4):1099-1108. PubMed ID: 33333592
[TBL] [Abstract][Full Text] [Related]
23. Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
George S; Barysauskas C; Serrano C; Oduyebo T; Rauh-Hain JA; Del Carmen MG; Demetri GD; Muto MG
Cancer; 2014 Oct; 120(20):3154-8. PubMed ID: 24923260
[TBL] [Abstract][Full Text] [Related]
24. Uterine Sarcoma: Clinical Presentation, Treatment and Survival Outcomes in Thailand.
Potikul C; Tangjitgamol S; Khunnarong J; Srijaipracharoen S; Thavaramara T; Pataradool K
Asian Pac J Cancer Prev; 2016; 17(4):1759-67. PubMed ID: 27221849
[TBL] [Abstract][Full Text] [Related]
25. A nomogram for predicting overall survival in patients with uterine leiomyosarcoma: a SEER population-based study.
Lu YJ; Wang H; Fang LY; Wang WJ; Song W; Wang Y; Huang YQ; Din ZL
Future Oncol; 2020 Apr; 16(10):573-584. PubMed ID: 32141309
[No Abstract] [Full Text] [Related]
26. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study.
Seagle BL; Sobecki-Rausch J; Strohl AE; Shilpi A; Grace A; Shahabi S
Gynecol Oncol; 2017 Apr; 145(1):61-70. PubMed ID: 28317559
[TBL] [Abstract][Full Text] [Related]
27. Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience.
Mahdavi A; Monk BJ; Ragazzo J; Hunter MI; Lentz SE; Vasilev SA; Tewari KS
Int J Gynecol Cancer; 2009 Aug; 19(6):1080-4. PubMed ID: 19820372
[TBL] [Abstract][Full Text] [Related]
28. Hysterectomy for uterine adenocarcinoma in the elderly: tumor characteristics, and long-term outcome.
Gayar OH; Robbins JR; Parikh K; Lu M; Buekers T; Munkarah A; Elshaikh MA
Gynecol Oncol; 2011 Oct; 123(1):71-5. PubMed ID: 21767871
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Chantharasamee J; Wong K; Potivongsajarn P; Qorbani A; Motamed N; Brackert S; Cohen J; Chmielowski B; Kalbasi A; Rao J; Nelson S; Singh A
Cancer Med; 2022 Aug; 11(15):2906-2912. PubMed ID: 35307963
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors and survival in patients treated surgically for recurrent metastatic uterine leiomyosarcoma.
Hoang HL; Ensor K; Rosen G; Leon Pachter H; Raccuia JS
Int J Surg Oncol; 2014; 2014():919323. PubMed ID: 25045534
[TBL] [Abstract][Full Text] [Related]
31. The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.
Schwameis R; Grimm C; Petru E; Natter C; Staudigl C; Lamm W; Koelbl H; Krainer M; Brodowicz T; Reinthaller A; Polterauer S
PLoS One; 2015; 10(8):e0133838. PubMed ID: 26248232
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
[TBL] [Abstract][Full Text] [Related]
33. Improved clinical trial enrollments for uterine leiomyosarcoma patients after gynecologic oncology partnership with a sarcoma center.
Lange SE; Liu J; Adkins DR; Powell MA; Van Tine BA; Mutch DG
Gynecol Oncol; 2016 Feb; 140(2):307-12. PubMed ID: 26718726
[TBL] [Abstract][Full Text] [Related]
34. Validation of tumor size as staging variable in the revised International Federation of Gynecology and Obstetrics stage I leiomyosarcoma: a population-based study.
Garg G; Shah JP; Liu JR; Bryant CS; Kumar S; Munkarah A; Morris RT
Int J Gynecol Cancer; 2010 Oct; 20(7):1201-6. PubMed ID: 20940535
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma.
Rauh-Hain JA; Hinchcliff EM; Oduyebo T; Worley MJ; Andrade CA; Schorge JO; George S; Muto MG; del Carmen MG
Int J Gynecol Cancer; 2014 Oct; 24(8):1434-40. PubMed ID: 25248114
[TBL] [Abstract][Full Text] [Related]
36. Long term survival outcomes of stage I mucinous ovarian cancer - A clinical calculator predictive of chemotherapy benefit.
Richardson MT; Mysona DP; Klein DA; Mann A; Liao CI; Diver EJ; Darcy KM; Tian C; She JX; Ghamande S; Van Le L; Kapp DS; Chan JK
Gynecol Oncol; 2020 Oct; 159(1):118-128. PubMed ID: 32828578
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
[No Abstract] [Full Text] [Related]
38. Influence of Comorbidity on the Risk of Death: A Single Institution Study of 1132 Women With Early-stage Uterine Cancer.
Elshaikh MA; Vance S; Kamal M; Burmeister C; Hanna RK; Rasool N; Siddiqui F
Am J Clin Oncol; 2017 Apr; 40(2):183-188. PubMed ID: 25222075
[TBL] [Abstract][Full Text] [Related]
39. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
40. Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor.
Burghaus S; Halmen S; Gass P; Mehlhorn G; Schrauder MG; Lux MP; Renner SP; Beckmann MW; Hein A; Thiel FC
Arch Gynecol Obstet; 2016 Aug; 294(2):343-51. PubMed ID: 26711836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
